Abbott has received approval from the US Food and Drug Administration (FDA) for its Epic Max stented tissue valve to treat aortic valve disease.

Part of the company’s Epic surgical valve platform, the Epic Max valve is intended for the treatment of people with aortic regurgitation or stenosis.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Designed to attain better haemodynamics, or blood flow, Epic Max features a low-profile frame that enables potential future transcatheter interventions for patients.

According to the company, bioprosthetic valves, such as Epic Max, can be used for patients who require valve replacement but cannot take blood-thinning medication.

Mechanical or bioprosthetic (tissue) valves will be used to replace diseased or damaged heart valves that cannot be repaired in an open-heart surgical procedure.

Abbott structural heart business senior vice-president Michael Dale said: “With Epic Max, we’re accomplishing two important things: First and foremost, we’re improving heart valve hemodynamics, which is the purpose of the procedure.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Secondly, we’re preserving options and ability for patient lifetime disease management, an ever more critical point of consideration in device therapy selection.”

University of Pennsylvania cardiovascular surgery division vice-chief Dr Joseph Bavaria said: “The aortic valve is one of the heart valves most commonly impacted by cardiovascular disease, frequently requiring replacement.

“Abbott’s Epic Max design optimises blood flow for patients and has a low profile that makes future cardiac interventions, if necessary, easier.”

In another development this month, Abbott announced positive late-breaking data from the TRILUMINATE Pivotal trial of its TriClip transcatheter edge-to-edge repair (TEER) system.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact